Edwards Lifesciences Corp. is poised to reap major benefits following the FDA's decision to expand the indications of two transcatheter aortic valve replacement (TAVR) devices. The company's Sapien 3 and XT transcatheter valves now will be an option for patients who are at intermediate risk for death or complications associated with open-heart surgery.